Literature DB >> 15620876

In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery.

Zhenghong Xu1, Wangwen Gu, Jun Huang, Hong Sui, Zhaohui Zhou, Yongxin Yang, Zhou Yan, Yaping Li.   

Abstract

The aim of the present work was to assess the merits of an actively targetable nanoparticles (ATN), PEG-coated biodegradable polycyanoacrylate nanoparticles (PEG-nanoparticles) conjugated to transferrin, for paclitaxel delivery. PEG-nanoparticles loading paclitaxel were prepared by solvent evaporation technique in advance. ATN were prepared by coupling of transferrin to PEG-nanoparticles. The results showed that the average encapsulation efficiency of ATN was 93.4+/-3.6% with particle size (101.4+/-7.2 nm) and zeta-potential (-13.6+/-1.1 mV). The paclitaxel loaded ATN exhibited a low burst effect with about only 16.2% drug release within the first phase. Subsequently, paclitaxel release profiles displayed a sustained release phase. The amount of cumulated paclitaxel release over 30 days was 81.6%. ATN exhibited a markedly delayed blood clearance in mice, and the paclitaxel level from ATN remained much higher at 24 h compared with that of free drug from paclitaxel injection. The distribution profiles of ATN in S-180 solid tumor-bearing mice after intravenous administration showed the tumor accumulation of paclitaxel increase with time, and the paclitaxel concentration in tumor was about 4.8 and 2.1 times higher than those from paclitaxel injection and PEG-nanoparticles at 6 h after intravenous injection. For mice treated with 20 mg/kg x 5 of ATN, the decrease in body weight was limited within 4% of the initial weight at 5 days after the final administration, and tumor regression was significantly observed with complete tumor regression for five out of nine mice. The tumor burden with ATN-treated mice was much smaller compared with free paclitaxel or NTN-treated mice. In addition, the life span of tumor-bearing mice was significantly increased when they were treated with ATN, in particular, three mice survived over 60 days. Thus, PEG-coated biodegradable polycyanoacrylate nanoparticles conjugated to transferrin could be an effective carrier for paclitaxel delivery.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15620876     DOI: 10.1016/j.ijpharm.2004.10.009

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  18 in total

1.  Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel.

Authors:  Deepti Pandita; Alka Ahuja; Viney Lather; Biju Benjamin; Tathagata Dutta; Thirumurthy Velpandian; Roop Krishen Khar
Journal:  AAPS PharmSciTech       Date:  2011-06-03       Impact factor: 3.246

Review 2.  Nanocarriers' entry into the cell: relevance to drug delivery.

Authors:  Hervé Hillaireau; Patrick Couvreur
Journal:  Cell Mol Life Sci       Date:  2009-06-05       Impact factor: 9.261

Review 3.  Optical imaging-guided cancer therapy with fluorescent nanoparticles.

Authors:  Shan Jiang; Muthu Kumara Gnanasammandhan; Yong Zhang
Journal:  J R Soc Interface       Date:  2009-09-16       Impact factor: 4.118

4.  The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors.

Authors:  Mukaddes Izci; Christy Maksoudian; Bella B Manshian; Stefaan J Soenen
Journal:  Chem Rev       Date:  2021-01-14       Impact factor: 60.622

Review 5.  Encapsulation of nucleic acids and opportunities for cancer treatment.

Authors:  Lisa Brannon-Peppas; Bilal Ghosn; Krishnendu Roy; Kenneth Cornetta
Journal:  Pharm Res       Date:  2007-02-15       Impact factor: 4.200

6.  Evaluation of two polymeric blends (EVA/PLA and EVA/PEG) as coating film materials for paclitaxel-eluting stent application.

Authors:  Xi Liu; Lei Lei; Jing-Wen Hou; Mu-Fei Tang; Sheng-Rong Guo; Zhong-Min Wang; Ke-Min Chen
Journal:  J Mater Sci Mater Med       Date:  2011-01-08       Impact factor: 3.896

Review 7.  The transferrin receptor and the targeted delivery of therapeutic agents against cancer.

Authors:  Tracy R Daniels; Ezequiel Bernabeu; José A Rodríguez; Shabnum Patel; Maggie Kozman; Diego A Chiappetta; Eggehard Holler; Julia Y Ljubimova; Gustavo Helguera; Manuel L Penichet
Journal:  Biochim Biophys Acta       Date:  2011-08-05

Review 8.  Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.

Authors:  Darren Lars Stirland; Joseph W Nichols; Seiji Miura; You Han Bae
Journal:  J Control Release       Date:  2013-10-02       Impact factor: 9.776

Review 9.  Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery.

Authors:  Lilian E van Vlerken; Tushar K Vyas; Mansoor M Amiji
Journal:  Pharm Res       Date:  2007-03-29       Impact factor: 4.200

Review 10.  Cancer active targeting by nanoparticles: a comprehensive review of literature.

Authors:  Remon Bazak; Mohamad Houri; Samar El Achy; Serag Kamel; Tamer Refaat
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-09       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.